<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735059</url>
  </required_header>
  <id_info>
    <org_study_id>KSEL0702</org_study_id>
    <nct_id>NCT00735059</nct_id>
  </id_info>
  <brief_title>Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures</brief_title>
  <official_title>Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EXcorLab GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nipro Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EXcorLab GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A current trend in dialysis membrane engineering is to maximize the permeability for larger
      low-molecular weight proteins while retaining albumin. Protein-leaking dialysis membranes do
      not meet these requirements. Particularly in convective procedures, such as
      hemodiafiltration, their albumin leakage is too high [10]. POLYNEPHRON™, the membrane which
      is built in to the new Nipro ELISIO® dialyzer, is a new dialysis membrane, produced by
      applying an innovative spinning technique. The incentive of its development was to improve
      the characteristics of existing dialysis membranes, i.e., realizing a steeper sieving profile
      for low-molecular weight proteins without significant loss of essential larger proteins at
      best biocompatibility properties, for a more adequate dialysis therapy. Purpose of the
      planned study is to demonstrate the superior performance at lower albumin loss in different
      dialysis procedures of the new Nipro ELISIO® dialyzer compared with a control dialyzer with
      regard to the removal of the whole range of uremic toxins.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>protein-bound toxin removal</measure>
    <time_frame>pre and post dialysis treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>low-molecular weight protein removal</measure>
    <time_frame>pre and post dialysis treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>small solute removal</measure>
    <time_frame>pre and post dialysis treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with dialyzer ELISIO 170H</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with dialyzer PES-170DS</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>treatment with the dialyzer ELISIO 170H</intervention_name>
    <description>one week of three consecutive dialysis treatments, &gt; 3 hours</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>treatment with the dialyzer PES-170DS</intervention_name>
    <description>one week of three consecutive dialysis treatments, &gt; 3 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  CKD stage 5 with hemodialysis or hemodiafiltration treatment for more than three
             months

          -  Hematocrit &gt;30 %

          -  Routine anticoagulation and erythropoietin regimen

          -  No vascular access related problems (A/V-fistula, graft or bi-flow catheter)

          -  No ongoing infection

          -  Signed informed consent form

        Exclusion Criteria:

          -  Inclusion criteria not met

          -  Known HIV or active hepatitis B or C infection (positive PCR). Pregnancy

          -  Unstable clinical condition (e.g. cardiac or vascular instability)

          -  Life expectancy less than 12 months

          -  Known coagulation problems

          -  Patients participating in another study interfering with the planned study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond Vanholder, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Ghent, Nephrology Section</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>August 20, 2009</last_update_submitted>
  <last_update_submitted_qc>August 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Horst-Dieter Lemke, Biochemist, Chief Executive Officer</name_title>
    <organization>EXcorLab GmbH</organization>
  </responsible_party>
  <keyword>dialysis membrane</keyword>
  <keyword>Polynephron</keyword>
  <keyword>Elisio H</keyword>
  <keyword>Polyethersulfone</keyword>
  <keyword>Diapes</keyword>
  <keyword>PES-DS</keyword>
  <keyword>online post-dilution hemodiafiltration</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>protein-bound toxins</keyword>
  <keyword>beta-2-microglobulin</keyword>
  <keyword>hemodialysis patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

